Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
Part of paid clinical trials in Evanston, Illinois.
- Sponsor
- Eugene F Yen, MD
- Study ID
- NCT04043897
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Microscopic Colitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rifaximin 550mg — DRUGRifaximin 550mg
Study Details
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
Key Dates
- Start date
- Jun 29, 2018
- Status verified
- Apr 2021
- Primary completion
- Dec 31, 2021
- Completion
- Dec 31, 2021
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: DrugPatients will receive open-label rifaximin 550mg tid x 4 weeks.
Primary Outcome Measure
Number of Subject Experiencing Remission of MC Symptoms [ Time Frame: 6 weeks ]
Central Contacts
- Daniel Amusin, BS847-570-3558
- Iris Chiou, BA847-570-2138
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NorthShore University HealthSystem | Evanston | Illinois | 60201 | Eugene Yen, MD (PRINCIPAL_INVESTIGATOR) Nora Joseph, MD (SUB_INVESTIGATOR) |
Find similar trials in Evanston, IL
By research site
Related Studies
- Enabling Microbiomics- Driven Personalized NutritionEnrolling By Invitation · Mayo Clinic · Rochester, Minnesota